Apollomics, Inc. (NASDAQ:APLM) Short Interest Down 50.5% in December

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 10,800 shares, a decline of 50.5% from the December 15th total of 21,800 shares. Approximately 1.6% of the shares of the company are sold short. Based on an average trading volume of 309,200 shares, the short-interest ratio is presently 0.0 days.

Apollomics Stock Performance

NASDAQ APLM traded down $0.21 during trading hours on Thursday, hitting $9.72. The company had a trading volume of 1,198 shares, compared to its average volume of 23,808. The business has a 50 day moving average of $10.24 and a 200-day moving average of $13.52. Apollomics has a 1-year low of $6.50 and a 1-year high of $99.00.

Institutional Trading of Apollomics

A hedge fund recently raised its stake in Apollomics stock. Exchange Traded Concepts LLC grew its position in Apollomics, Inc. (NASDAQ:APLM) by 247.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,259,117 shares of the company’s stock after acquiring an additional 896,316 shares during the quarter. Exchange Traded Concepts LLC owned about 1.41% of Apollomics worth $179,000 at the end of the most recent reporting period. 19.13% of the stock is currently owned by hedge funds and other institutional investors.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.